ClinicalTrials.gg
CompletedNCT07892365Updated Oct 23, 2026

The Effect of Chewing Gum on Pain and State Anxiety During Intravenous Blood Sampling

An interventional study of Chewing gum was done during the intravenous blood draw procedure in Intravenous Blood Sampling and Pain and Anxiety, sponsored by Dicle University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Dicle University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Oct 2025, registered Oct 2026).
Updated Oct 23, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study was conducted to investigate the effect of chewing gum during intravenous blood sampling on pain and anxiety levels in individuals.

Read the detailed description

The sample consisted of 170 individuals (85 in the experimental group and 85 in the control group) who attended the Gercüş Family Health Center in Batman between October 2025 and May 2026, agreed to participate in the study, and met the inclusion criteria.

02

Conditions studied

  • Intravenous Blood Sampling
  • Pain and Anxiety

Keywords

  • Intravenous Blood Sampling
  • Chewing Gum
  • pain
  • anxiety
  • nursing
03

In context

Pain

2,450 studies on the registry are indexed under Pain; 945 are open to participants now.

This study's enrollment of 170 is above the median of 70 across 2,101 interventional studies indexed under Pain.

Browse Pain studies →

Lead sponsor

Dicle University is the lead sponsor of 26 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Volunteers who agreed to participate in the study,
  • Individuals who will undergo intravenous blood sampling,
  • Aged between 18-65,
  • Those who have the cognitive ability to understand and answer the questions during the study,
  • Individuals who have not had any blood sampling experience in the past month were included in the study.

Exclusion criteria

Exclusion Criteria:

  • Individuals with any anatomical or functional issues related to the mouth, jaw, temporomandibular joint, or dental health,
  • Those with neurological disorders or conditions that could hinder chewing, such as difficulty swallowing (dysphagia),
  • Anyone with any skin or vascular problems in the area where the procedure will be done,
  • Those with a history of psychiatric medication use or a diagnosed anxiety disorder,
  • Individuals who have taken analgesic medication for any reason in the past 24 hours were not included in the study.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
170 participants (actual)

Study arms

  • Experimental
    Chewing Gum

    Participants in the experimental group chewed gum during intravenous blood sampling

    Procedure: Chewing gum was done during the intravenous blood draw procedure

  • No intervention
    no gum chewing allowed

    whereas those in the control group received routine care.

Interventions

  • ProcedureChewing gum was done during the intravenous blood draw procedure

    Participants in the experimental group chewed gum during the intravenous blood sampling procedure. Participants in the control group underwent the routine blood sampling procedure without chewing gum. Pain and state anxiety levels were assessed before and after the procedure using the Visual Analog Scale (VAS) and the State Anxiety Inventory (STAI-I).

06

What researchers measure

Primary outcomes

  1. pain level-Visual Analog Scale (VAS)

    Pain level was assessed using the Visual Analog Scale (VAS) before and after the intravenous blood sampling procedure in both the experimental and control groups.

    Time frame: Before and immediately after the intravenous blood sampling procedure.

  2. state anxiety level- state anxiety inventory(STAI-I)

    State anxiety was assessed using the State Anxiety Inventory (STAI-I) before and after the intravenous blood sampling procedure in both the experimental and control groups.

    Time frame: Before and immediately after the intravenous blood sampling procedure.

07

Study locations

1 site
  • Gercüş Family Health Center in Batman
    Batman, Gercüş, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in May 2026, 7 months.

Of 1,253 non-industry interventional studies with no phase under Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 29. This study's 7 months is below that.

Counting every sponsor, half of 1,276 studies reached it within 11 months; a quarter within 5 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2026
First posted
Oct 23, 2026
StartActual
Oct 17, 2025
Primary completionActual
May 22, 2026
CompletionActual
May 22, 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07892365
Lead sponsor
Dicle University
Responsible party
Tuğba Uğur (Nurse, Dicle University) — Principal investigator
First posted
Oct 23, 2026
Start date
Oct 17, 2025
Primary completion
May 22, 2026
Completion
May 22, 2026
Last update
Oct 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion